Breast cancer is the most common cancer in Canadian women,” said Dr. Jeff Wrana, Senior Investigator and the Mary Janigan Research Chair in Molecular Cancer Therapeutics at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, and an International Scholar of the Howard Hughes Medical Institute. “Our hope with this technology is to eventually provide individualized analysis to breast cancer patients and their oncologists so that they are better informed and empowered to select a treatment best suited to them.
In the future, this tool may be used to analyze other types of cancer and could be used to predict an individual’s response to particular drugs.
“This research brings us one step closer to delivering individualized medicine in which healthcare professionals will be able to provide more accurate and personalized diagnoses and treatments,” said Dr. Jim Woodgett, Director of Research for the Samuel Lunenfeld Research Institute of Mount Sinai Hospital.
The research was funded by Genome Canada with funds from Ontario Genomics Institute, and the Canadian Breast Cancer Foundation (CBCF) – Ontario Region. The CBCF’s Interim CEO Beth Easton said the Foundation, “is pleased to play a role, along with others, in supporting the basic science behind this exciting development for breast cancer patients.”
To bring this technology to patients, Mount Sinai Hospital is working to partner with the biotechnology industry, and estimates that the tool will be available to healthcare providers within the next five years. Visit the DyNeMo BioSystems website for more.
About the Samuel Lunenfeld Research Institute of Mount Sinai Hospital
The Samuel Lunenfeld Research Institute of Mount Sinai Hospital, a University of Toronto affiliated research centre established in 1985, is one of the world’s premier centres in biomedical research. Thirty-four principal investigators lead research in diabetes, cancer biology, epidemiology, stem cell research, women’s and infants’ health, neurobiology and systems biology. For more information on the Samuel Lunenfeld Research Institute, please visit www.lunenfeld.ca.
The Institute of Cancer Research
The Institute of Cancer Research is Europe's leading cancer research centre with expert scientists working on cutting edge research. In 2009, The Institute of Cancer Research marks its 100 years of world leading research into cancer prevention, diagnosis and treatment. The Institute is a charity that relies on voluntary income. It is one of the world's most cost-effective major cancer research organisations with over 95p in every £ directly supporting research. For more information visit www.icr.ac.uk .
Genome Canada is a private, non-profit corporation, and the primary funding and information resource relating to genomics and proteomics research in Canada. Its principal goal is to position Canada among the world leaders in genomics and proteomics research. Its mandate is to develop and implement a national strategy in genomics and proteomics research for the benefit of all Canadians in key selected areas such as agriculture, environment, fisheries, forestry, animal and human health, and new technology. For this purpose, it has received $840 million in funding from the Canadian government and co-funding from other partners over eight years, allowing it to invest a total of $1.6 billion in 131 innovative research projects and technology platforms. To learn more about Genome Canada, please visit the website at www.genomecanada.ca .
Canadian Breast Cancer Foundation – Ontario Region
Samuel Lunenfeld Research Institute
Mount Sinai Hospital
416 586-4800 ext. 2046